Table 2.

Concentrations of complement components in the study sample.

A. COMPARISONS of C3a, C5a and C5b-9 SERUM CONCENTRATIONS IN BD PATIENTS AND HEALTHY CONTROLS
Complement component	BD patient group (n = 30)	Control group (n = 30)	p
C3a [ng/ml]	968.62 ± 82.65	638.78 ± 146.96	0.000001
C5a [ng/ml]	203.56 ± 128.56	74.00 ± 63.01	0.000001
C5b-9 [ng/ml]	408.94 ± 4020.96	267.78 ± 303.48	0.0002
B. COMPARISONS OF C3a, C5a AND C5b-9 SERUM CONCENTRATIONS IN BD TYPE I PATIENTS AND HEALTHY CONTROLS
Complement component	BD type I patient group (n = 22)	Control group (n = 30)	p
C3a [ng/ml]	959.36 ± 67.20	638.78 ± 146.96	0.000001
C5a [ng/ml]	191.49 ± 117.65	74.00 ± 63.01	0.000001
C5b-9 [ng/ml]	369.21 ± 147.31	267.78 ± 303.48	0.0016
C. COMPARISONS OF C3a, C5a AND C5b-9 SERUM CONCENTRATIONS IN BD TYPE II PATIENTS and HEALTHY CONTROLS
Complement component	BD type II patient group (n = 8)	Control group (n = 30)	p
C3a [ng/ml]	994.08 ± 117.26	638.78 ± 146.96	0.000001
C5a [ng/ml]	236.75 ± 158.86	74.00 ± 63.01	0.0001
C5b-9 [ng/ml]	518.18 ± 149.58	267.78 ± 303.48	0.0007
D. COMPARISONS of C3a, C5a and C5b-9 SERUM CONCENTRATIONS IN BD TYPE I PATIENTS AND BD TYPE II PATIENTS
plasma factor	BD type I patient group (n = 22)	BD type II patient group (n = 8)	p
C3a [ng/ml]	959.36 ± 67.20	994.08 ± 117.26	0.0575
C5a [ng/ml]	191.49 ± 117.65	236.75 ± 158.86	0.6559
C5b-9 [ng/ml]	369.21 ± 147.31	518.18 ± 149.58	0.0292